Table 1. Input parameters for the base-case analysis.
Category. | Description | Value | References |
---|---|---|---|
Cost | R&D costs associated with the development of antineoplastic and immunomodulating agents, capitalized and risk adjusted. Unadjusted for inflation and currency change. | €4937.4 million | Wouters et al. (2020) [17] |
Cost of manufacturing per gram of mAbs | €55 | Ou Yang et al. (2019) [24] | |
R&D costs associated with each new indication. | €347 million | Nosengo (2016) [18] | |
Incidence rate per 100,000 | Multiple myeloma | 7.6 | IARC [1] |
Melanoma | 21.7 | IARC [1] | |
Lung Cancer | 69.5 | IARC [1] | |
Head and neck cancer | 21.8 | IARC [1] | |
Hodgkin Lymphoma | 2.5 | IARC [1] | |
Bladder cancer | 26.3 | IARC [1] | |
Gastric and Oesophagus cancer | 32.1 | IARC [1] | |
Cervical cancer | 13.3 | IARC [1] | |
Non-Hodgkin Lymphoma | 19.2 | IARC [1] | |
Liver cancer | 14.4 | IARC [1] | |
Non melanoma skin cancer | 80.3 | IARC [1] | |
Kidney cancer | 19.3 | IARC [1] | |
Oesophagus cancers | 8.0 | IARC [1] | |
Corpus uteri cancer | 33.7 | IARC [1] | |
Colorectum cancer | 68.1 | IARC [1] | |
Breast cancer | 142.0 | IARC [1] | |
Patent expiry (year) | Daratumumab | 2025 | Busse & Lüftner (2019) [21] |
Pembrolizumab | 2028 | Busse & Lüftner (2019) [21] | |
Profit margin (in %) | Profit margin | 20% | Uyl-de Groot & Löwenberg (2018) [9] |
mAbs: Monoclonal antibodies.